Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 1/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29777459 | 1.00 | ACE (0.55) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL155067 | 0.93 | ACE (0.62) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL30051559 | 0.93 | ACE (0.62) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL155066 | 0.93 | ACE (0.62) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL4168006 | 0.91 | ACE (0.60) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL4167998 | 0.91 | ACE (0.60) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL28116177 | 0.90 | ACE (0.58) | ACEDPP4PREPFAPDPP8 | |
| Glycyl Proline SCHEMBL28116179 | 0.90 | ACE (0.58) | ACEDPP4PREPFAPDPP8 | |
| SCHEMBL31364129 | 0.88 | ACE (0.56) | ACEDPP4PREPFAPDPP8 | |
| SCHEMBL31670618 | 0.88 | ACE (0.45) | ACEDPP4PREPFAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| WO-2025110358-A1 | LONG-ACTING RECOMBINANT ALPHA-1 ANTITRYPSIN AND USE THEREOF | 아주대학교산학협력단 | 2025-05-30 | — | — | WO | claimed |
| CN-119855612-A | Radionuclide coupling medicine, pharmaceutical composition and application thereof | 同宜医药（苏州）有限公司 | 2025-04-18 | — | — | CN | claimed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | claimed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | claimed |
| US-20240101599-A1 | PEPTIDE, CELL GROWTH PROMOTER, PROTEIN PRODUCTION PROMOTER, CULTURE MEDIUM, CELL GROWTH METHOD USING PEPTIDE, AND PROTEIN PRODUCTION METHOD USING PEPTIDE | Maruhachi Muramatsu, Inc. (JP) | 2024-03-28 | — | — | US | claimed |
| WO-2024051794-A1 | RADIONUCLIDE-DRUG CONJUGATE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 同宜医药（苏州）有限公司 | 2024-03-14 | — | — | WO | claimed |
| US-20230374112-A1 | Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof | BDC CAPITAL INC. (CA) | 2023-11-23 | — | — | US | claimed |
| WO-2023202654-A1 | COMPOUND AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-10-26 | — | — | WO | claimed |
| CN-116106552-A | Kit for targeting detection of collagen in solution and application of kit in liver fibrosis diagnosis | 兰州大学 | 2023-05-12 | — | — | CN | claimed |
| CN-113512094-B | Covalent photo-crosslinked polypeptide and collagen bionic material formed by covalent photo-crosslinked polypeptide self-assembly | 兰州大学 | 2023-04-14 | — | — | CN | claimed |
| EP-3395373-B1 | METHOD FOR LABELLING A BIOLOGICAL TARGETING MOLECULE VIA CONJUGATION WITH A RADIOISOTOPE SUITABLE FOR PET OR SPECT IMAGING | GE HEALTHCARE LTD (GB) | 2022-10-19 | — | — | EP | claimed |
| WO-2022137357-A1 | PEPTIDE, CELL GROWTH PROMOTER, PROTEIN PRODUCTION PROMOTER, CULTURE MEDIUM, CELL GROWTH METHOD USING PEPTIDE, AND PROTEIN PRODUCTION METHOD USING SAID PEPTIDE | 株式会社マルハチ村松 | 2022-06-30 | — | — | WO | claimed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | claimed |
| US-20260144915-A1 | Biomimetic Vascularized 3D Reinforced PCL/Collagen/In-Situ HAPclay Scaffolds With Iliotibial Band Cavity for Anterior Cruciate Ligament (ACL) Regeneration | SANFORD HEALTH (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | disclosed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | disclosed |
| CN-114209880-A | Preparation method of biological composite material of ordered mineralized polypeptide, product and application thereof | 浙江大学 | 2022-03-22 | — | — | CN | disclosed |
| US-4719200-A | Amino acid derivatives and antihypertensive drugs containing the same | AJINOMOTO CO., INC. (JP) | 1988-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885DPP4 43/4885PREP 4/4885 |
| US-20260144915-A1 | Biomimetic Vascularized 3D Reinforced PCL/Collagen/In-Situ HAPclay Scaffolds With Iliotibial Band Cavity for Anterior Cruciate Ligament (ACL) Regeneration | PLOD3, BCAT1, COL14A1 | ACE 2460/4885DPP4 2242/4885PREP 610/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | ACE 2388/4885DPP4 1205/4885PREP 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.